Digital Event | 8.00 - 3.30 EST

8:55 am Chair’s Opening Remarks

Emerging Assays Which Will Streamline Epigenetic Drug Discovery & Development

9:00 am Evaluating Current Exploration into the Single Cell Space to Precisely Understand Epigenetic Behaviour

  • Paloma Cejas Assistant Director for Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute


  • Moving away from messy bulk, invasive analysis assays of millions of cells to better understand disease pathways
  • Elevating understanding of epigenetic marks and gene expression by clustering single cell studies into sub-populations
  • Increasing pathway specificity with single cell clustering to ensure patient safety

9:30 am Opportunities for non-invasive cancer detection and classification through epigenetic analysis of cell-free DNA


  • Exploring novel methods for epigenetic analysis of cell-free DNA
  • Utilizing cell-free DNA methylation analysis for non-invasive cancer detection and identifying clinically actionable resistance phenotypes
  • Examining the role of epigenetic liquid biopsies in precision oncology in the future

Unveiling Novel Approaches to Epigenetic Therapy

10:00 am Targeting Transcription Factor-BAF Interactions in Cancer


  • Understanding how transcription factors make for compelling drug targets, but have been historically hard-to-drug
  • Spotlighting transcription factors involvement with the BAF chromatin remodeling complex to open chromatin
  • Developing a drug discovery platform to inhibit TF-BAF interactions; the Foghorn approach

10:30 am
Morning Break & Structured Networking

11:00 am Regulating Gene Expression by Targeting Regulatory RNAs: A Novel Therapeutic Approach


  • Highlighting regRNAs, non-coding transcripts derived from gene regulatory elements, as key regulators of transcription
  • Targeting regRNAs with antisense oligonucleotides (ASO) leads to specific modulation of gene expression
  • Unveiling the potential of ASOs targeting regRNAs have to be a novel class of programmable therapeutics for a range of diseases

11:30 am CFT8634, a Potent & Selective Degrader of BRD9 for the Treatment of SMARCB1-perturbed Cancers


  • CFT8634 is an orally bioavailable heterobifunctional degrader that induces ubiquitination and degradation of BRD9 by the proteasome.
  • CFT8634 promotes potent and selective BRD9 degradation and dosedependent tumor growth inhibition in cell- and patient-derived preclinical SMARCB1-perturbed xenograft models.
  • Degradation of BRD9 by CFT8634 offers a promising and novel approach to address this class of difficult-to-treat diseases.

12:00 pm Activation of Latent Oncogenic Viruses as a Form of Targeted Cancer Therapy


  • Outlining the Epstein-Barr virus (EBV), a ubiquitous lymphotropic herpesvirus, associated with a heterogenous group of malignancies.
  • Demonstrating how Nanatinostat induces expression of the EBV protein kinase, BGLF4, which activates the antiviral ganciclovir via phosphorylation to block DNA synthesis and trigger apoptosis.
  • Discussing our phase 1b/2 clinical data which demonstrated promising efficacy and safety in patients with various subtypes of relapsed/refractory Epstein-Barr virus-positive lymphoma

12:30 pm
Lunch & Structured Networking

Spearheading Conversation Around Drug Resistance Across Epigenetic Drug Development

1:30 pm Studying Neuroendocrine Transdifferentiation as a Mechanism of Drug Resistance

  • Henry Long Scientific Director Center for Functional Cancer Epigenetics, Dana Farber Cancer Institute


  • How do mutiple tumors acquire resistance to targeted therapeutics by transdifferentiation?
  • Understanding if there is a common epigenetic state in the resulting neuroendocrine tumor type
  • Exploring how intratumoral heterogeneity is detected in these tumors

2:00 pm PANEL DISCUSSION: Let’s Talk About Epigenetic Drug Resistance

  • Claes Wahlestedt Associate Dean & Center Director for Therapeutic Innovation; Chief Scientific Officer, University of Miami Miller School of Medicine; Epigenetix
  • Paloma Cejas Assistant Director for Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute
  • Alon Goren Assistant Professor, University of San Diego California (UCSD)


  • Exploring the ways in which drug resistance develops in relation to epigenetics
  • Considering epigenetic mechanisms implicit in drug resistance
  • Combating drug resistance with epigenetic drugs in combinational therapies

Revising How We Approach Translational Medicine to Enhance Epigenetic Research & Development

2:45 pm Translating Established Targets: Potent anti-Tumor Activity of a KAT6A/KAT6B Inhibitor PF-9363/CTx-648 in KAT6A dysregulated ER+ Breast Cancer


  • Understanding molecular dysregulation of KAT6A has been observed in several cancers, including amplifications in breast, lung, ovarian cancer along with oncogenic fusions in AML
  • Examining CTx-648 (PF-9363), a first-in-class potent KAT6A/KAT6B inhibitor that possess high selectivity versus other MYST family members (KAT7, KAT5, KAT8)
  • Learn how CTx-648 (PF-9363) inhibits expression of ESR1 expression leading to potent antitumor activity in ER+ breast cancer models

2:50 pm End of Conference

3:15 pm Chair’s Closing Remarks